Drug class in one race
VEGF-A drugs for Non-Small Cell Lung Cancer
11 tracked VEGF-A drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the VEGF-A page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
8 approved / phase 43 Phase 3
Head-to-head evidence: Alymsys (bevacizumab-maly) vs BAT1706 · Alymsys (bevacizumab-maly) vs Bevacizumab · Alymsys (bevacizumab-maly) vs HLX04 · Alymsys (bevacizumab-maly) vs LY01008 · Alymsys (bevacizumab-maly) vs PF-06439535 · Alymsys (bevacizumab-maly) vs bevacizumab-awwb